Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Dean Liu -- 1321 2022-11-30 01:48:43

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. MAb114. Encyclopedia. Available online: https://encyclopedia.pub/entry/37313 (accessed on 01 October 2026).
HandWiki. MAb114. Encyclopedia. Available at: https://encyclopedia.pub/entry/37313. Accessed October 01, 2026.
HandWiki. "MAb114" Encyclopedia, https://encyclopedia.pub/entry/37313 (accessed October 01, 2026).
HandWiki. (2022, November 30). MAb114. In Encyclopedia. https://encyclopedia.pub/entry/37313
HandWiki. "MAb114." Encyclopedia. Web. 30 November, 2022.
MAb114
Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:MAb114

mAb114 is a monoclonal antibody that is being evaluated as a treatment for Ebola virus disease. Its discovery was led by the laboratory of Nancy Sullivan at the United States National Institute of Health Vaccine Research Center and J. J. Muyembe-Tamfum from the Institut National pour la Recherche Biomedicale (INRB) in the Democratic Republic of Congo, working in collaboration with the Institute of Biomedical Research and the United States Army Medical Research Institute of Infectious Diseases. mAb114 was isolated from the blood of a survivor of the 1995 outbreak of Ebola virus disease in Kikwit, Democratic Republic of Congo roughly ten years later. In early 2018, a Phase 1 clinical trial of mAb114 was conducted by Martin Gaudinski within the Vaccine Research Center Clinical Trials Program that is led by Julie E. Ledgerwood. mAb114 is also being evaluated during the 2018 North Kivu Ebola outbreak. mAb114 has also shown success with lowering the mortality rate from ~70% to about 34%. In August 2019, Congolese health authorities, the World Health Organization, and the U.S. National Institutes of Health promoted the use of mAb114, alongside REGN-EB3, a similar Regeneron-produced monoclonal antibody treatment, over other treatments yielding higher mortality rates, after ending clinical trials during the outbreak.

monoclonal antibody clinical trial ebola

References

  1. "Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody". Science 351 (6279): 1339–42. March 2016. doi:10.1126/science.aad5224. PMID 26917593. Bibcode: 2016Sci...351.1339C.  https://dx.doi.org/10.1126%2Fscience.aad5224
  2. Clinical trial number NCT03478891 for "Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT03478891
  3. "Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study". Lancet 393 (10174): 889–898. March 2019. doi:10.1016/S0140-6736(19)30036-4. PMID 30686586.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6436835
  4. "Structural and molecular basis for Ebola virus neutralization by protective human antibodies". Science 351 (6279): 1343–6. March 2016. doi:10.1126/science.aad6117. PMID 26917592. Bibcode: 2016Sci...351.1343M.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5241105
  5. "Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection". Nature 477 (7364): 344–8. August 2011. doi:10.1038/nature10380. PMID 21866101. Bibcode: 2011Natur.477..344C.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3230319
  6. "Ebola virus entry requires the cholesterol transporter Niemann-Pick C1". Nature 477 (7364): 340–3. August 2011. doi:10.1038/nature10348. PMID 21866103. Bibcode: 2011Natur.477..340C.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3175325
  7. Hayden, Erika Check (2016-02-26). "Ebola survivor's blood holds promise of new treatment". Nature. doi:10.1038/nature.2016.19440. ISSN 1476-4687. https://www.nature.com/news/ebola-survivor-s-blood-holds-promise-of-new-treatment-1.19440. 
  8. "NIH begins testing Ebola treatment in early-stage trial". National Institutes of Health (NIH). 2018-05-23. https://www.nih.gov/news-events/news-releases/nih-begins-testing-ebola-treatment-early-stage-trial. 
  9. "NIH VideoCast - CC Grand Rounds: Response to an Outbreak: Ebola Virus Monoclonal Antibody (mAb114) Rapid Clinical Development". https://videocast.nih.gov/summary.asp?Live=31594&bhcp=1. 
  10. "Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases". Ridgeback Biotherapeutics LP. https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-licensing-of-mab114-an-experimental-ebola-treatment-from-the-national-institute-of-allergy-and-infectious-diseases-300765146.html. 
  11. "About Us". https://www.ridgebackbio.com/about-us. 
  12. "Ridgeback Biotherapeutics LP Announces Orphan Drug Designation for mAb114". Ridgeback Biotherapeutics LP. https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-orphan-drug-designation-for-mab114-300859467.html. 
  13. Check Hayden, Erika (May 2018). "Experimental drugs poised for use in Ebola outbreak". Nature 557 (7706): 475–476. doi:10.1038/d41586-018-05205-x. ISSN 0028-0836. PMID 29789732. Bibcode: 2018Natur.557..475C.  https://dx.doi.org/10.1038%2Fd41586-018-05205-x
  14. WHO: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions for Ebola virus Disease. https://www.who.int/emergencies/ebola/MEURI-Ebola.pdf
  15. Mole, Beth (2019-08-13). "Two Ebola drugs boost survival rates, according to early trial data". https://arstechnica.com/science/2019/08/two-ebola-drugs-boost-survival-rates-according-to-early-trial-data/. 
  16. "Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates". 2019-08-12. https://www.nih.gov/news-events/news-releases/independent-monitoring-board-recommends-early-termination-ebola-therapeutics-trial-drc-because-favorable-results-two-four-candidates. 
  17. McNeil, Donald G. (12 August 2019). "A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo". The New York Times. https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html. 
  18. Kingsley-Hall, Alison. "Congo's experimental mAb114 Ebola treatment appears successful: authorities | Central Africa". http://www.theafricareport.com/Central-Africa/congos-experimental-mab114-ebola-treatment-appears-successful-authorities.html. 
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 1.3K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 30 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback